Skip to main content
BBIO
NASDAQ Life Sciences

BridgeBio Q2 revenue triples to $222M; CEO adopts 10b5-1 plan; $934M preferred financing closes post-quarter

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$85.5
Mkt Cap
$16.598B
52W Low
$45.395
52W High
$93.415
52W Position info
88% above low
Off High info
8.5% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

BBIO sits 88% above its 52-week low of $45.395.

Summary

BridgeBio's Q2 2026 revenue surged to $222M on Attruby sales, while the company disclosed a new CEO trading plan, a $500M buyback, and a post-quarter $934M preferred stock financing — reshaping its capital structure ahead of key regulatory catalysts.


Key Events · Earnings and Guidance · BBIO

  • Attruby Revenue Triples

    Net product revenue reached $222.4 million in Q2 2026, up from $71.5 million a year ago, driven by continued U.S. commercial expansion.

  • CEO Adopts 10b5-1 Trading Plan

    CEO Neil Kumar adopted a Rule 10b5-1 plan on May 13, 2026, covering potential sales of up to 120,000 shares plus shares from RSU/PSU vesting, with sales not permitted before mid-August 2026.

  • $500M Share Buyback Program

    The board authorized a $500 million repurchase program in May 2026; through June 30, 1.9 million shares were bought back for $127.5 million at an average price of $66.96.

  • Convertible Notes Now Convertible

    The $550 million 2027 Notes and $575 million 2031 Notes became convertible from July 1 through September 30, 2026, adding potential near-term dilution pressure.


Analysis · BBIO · Life Sciences

Attruby's commercial momentum is the headline, with net product revenue reaching $222.4 million in Q2 2026 — more than triple the year-ago quarter. While the company remains unprofitable, the net loss narrowed, and it ended June with $720 million in cash and equivalents. More importantly, the capital structure is in flux: the 2027 and 2031 notes are now convertible, and just after the quarter closed, BridgeBio raised $933.9 million in convertible preferred stock from Sixth Street and KKR. That deal, alongside a new $500 million buyback program and a CEO 10b5-1 trading plan, signals a company aggressively managing its balance sheet and dilution ahead of multiple upcoming PDUFA dates.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BBIO was trading at $85.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.6B. The 52-week trading range was $45.40 to $93.42. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BBIO - Latest Insights

BBIO
Oct 29, 2026, 4:52 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $70.69
Real-time Price: $78.93 info
Change: +$8.24 (+12%) info
Market Cap: $15.23B info
BBIO
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.44
Real-time Price: $78.93 info
Change: +$7.49 (+10%) info
Market Cap: $15.23B info
BBIO
Oct 29, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $70.67
Real-time Price: $78.93 info
Change: +$8.27 (+12%) info
Market Cap: $15.23B info
BBIO
Oct 13, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $65.75
Real-time Price: $78.93 info
Change: +$13.18 (+20%) info
Market Cap: $15.23B info
BBIO
Oct 11, 2026, 2:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $78.93 info
Change: +$13.58 (+21%) info
Market Cap: $15.23B info